Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Jubilant Therapeutics Receives FDA Clearance for JBI-802 IND

contractpharmaJanuary 06, 2022

Tag: JBI-802 , Jubilant Therapeutics , Solid Tumors

PharmaSources Customer Service